 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- CLM-101 / National OncoVenture, CellabMed
A phase Ib/IIa study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of YYB101, hepatocyte growth factor neutralizing humanized monoclonal antibody, in combination with irinotecan in metastatic or recurrent colorectal cancer patients (NOV110501-201) () - Jul 27, 2023 - Abstract #ESMO2023ESMO_2227;
P1b/2a
Conclusions The YYB101 and irinotecan combination showed modest efficacy and tolerable adverse events in refractory metastatic/recurrent CRC. Ongoing biomarker analyses aim to identify genomic and transcriptomic variables associated with long-term disease control.
- || CLM-101 / National OncoVenture, CellabMed
Trial completion, Trial completion date, Trial primary completion date, Combination therapy, Metastases: NOV110501-201: To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of YYB101 With Irinotecan, Patients Who Are Metastatic or Recurrent Colorectal Cancer Patients (clinicaltrials.gov) - Nov 14, 2022
P1b/2a, N=35, Completed, Sponsor: CellabMED
Ongoing biomarker analyses aim to identify genomic and transcriptomic variables associated with long-term disease control. Unknown status --> Completed | Trial completion date: May 2021 --> Dec 2021 | Trial primary completion date: Jun 2020 --> Dec 2021
- YYB101 / Yooyoung Pharma, National OncoVenture, YYB-103 / Yooyoung Pharma, CellabMed
A Novel CAR-T Cell Therapy Strategy to Inhibit Hepatocyte Growth Factor in Solid Tumor (Poster Board Number: Tu-179; Hall D) - Apr 20, 2022 - Abstract #ASGCT2022ASGCT_685;
Our experimental results showed that inhibition of HGF could be one strategy to improve the efficacy of CAR-T in solid tumors. Further study is ongoing to confirm experimental evidences that our new type of CAR-T, YYB-101 scFv-releasing CAR-T, actually acts on the immunosuppressive tumor microenvironment of solid tumors.
- | YYB-101 / National OncoVenture, CellabMed
Trial completion: Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy (clinicaltrials.gov) - May 13, 2021
P1, N=39, Completed, Sponsor: CellabMED
Further study is ongoing to confirm experimental evidences that our new type of CAR-T, YYB-101 scFv-releasing CAR-T, actually acts on the immunosuppressive tumor microenvironment of solid tumors. Recruiting --> Completed
- | YYB101 / Yooyoung Pharma, National OncoVenture
Journal: YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation. (Pubmed Central) - Feb 9, 2021
Recruiting --> Completed YYB-101 can be examined as a new therapeutic agent for the treatment of patients with ovarian cancer.
- || irinotecan / Generic mfg.
Clinical, P1 data, Journal, PD(L)-1 Biomarker, IO Biomarker: First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients. (Pubmed Central) - Jun 17, 2020
P1
Based on this phase I trial, a phase II study on the YYB101 + irinotecan combination in refractory metastatic colorectal cancer patients is planned. ClinicalTrials.gov Identifier: NCT02499224.
- YYB-101 / National OncoVenture, CellabMed
Trial primary completion date: Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy (clinicaltrials.gov) - Mar 23, 2016
P1, N=39, Recruiting, Sponsor: National OncoVenture
ClinicalTrials.gov Identifier: NCT02499224. Trial primary completion date: Dec 2015 --> Oct 2016
- YYB-101 / National OncoVenture, CellabMed
New P1 trial: Safety and Pharmacokinetics Study of YYB101 in Advanced Solid Tumors Patients Who Are Refractory to Standard Therapy (clinicaltrials.gov) - Jul 16, 2015
P1, N=39, Recruiting, Sponsor: National OncoVenture